Faron Pharmaceuticals Oy

DB:4FR Stock Report

Market Cap: €208.0m

Faron Pharmaceuticals Oy Management

Management criteria checks 2/4

We currently do not have sufficient information about the CEO.

Key information

Juho Jalkanen

Chief executive officer

€511.7k

Total compensation

CEO salary percentage77.8%
CEO tenureless than a year
CEO ownershipn/a
Management average tenureless than a year
Board average tenure1.3yrs

Recent management updates

Recent updates

CEO Compensation Analysis

How has Juho Jalkanen's remuneration changed compared to Faron Pharmaceuticals Oy's earnings?
DateTotal CompensationSalaryCompany Earnings
Jun 30 2024n/an/a

-€32m

Mar 31 2024n/an/a

-€31m

Dec 31 2023€512k€398k

-€31m

Sep 30 2023n/an/a

-€30m

Jun 30 2023n/an/a

-€29m

Mar 31 2023n/an/a

-€29m

Dec 31 2022€635k€539k

-€29m

Sep 30 2022n/an/a

-€26m

Jun 30 2022n/an/a

-€24m

Mar 31 2022n/an/a

-€22m

Dec 31 2021€450k€381k

-€21m

Sep 30 2021n/an/a

-€21m

Jun 30 2021n/an/a

-€20m

Mar 31 2021n/an/a

-€19m

Dec 31 2020€424k€324k

-€17m

Sep 30 2020n/an/a

-€16m

Jun 30 2020n/an/a

-€14m

Mar 31 2020n/an/a

-€14m

Dec 31 2019€273k€257k

-€13m

Sep 30 2019n/an/a

-€13m

Jun 30 2019n/an/a

-€12m

Mar 31 2019n/an/a

-€16m

Dec 31 2018€361k€221k

-€20m

Sep 30 2018n/an/a

-€24m

Jun 30 2018n/an/a

-€28m

Mar 31 2018n/an/a

-€25m

Dec 31 2017€388k€235k

-€21m

Compensation vs Market: Juho's total compensation ($USD533.94K) is below average for companies of similar size in the German market ($USD837.31K).

Compensation vs Earnings: Juho's compensation has been consistent with company performance over the past year.

CEO

Juho Jalkanen (46 yo)

less than a year

Tenure

€511,731

Compensation

Dr. Juho Markku Jalkanen, M.D., MSc & Ph D., is Founder of Faron Pharmaceuticals Oy and serves as its Chief Executive Officer and Director since May 1, 2024 and served as its Chief Operating Officer since...

Leadership Team

NamePositionTenureCompensationOwnership
Juho Jalkanen
Founderless than a year€511.73kno data
Yrjö Erik Wichmann
Interim Chief Financial Officerless than a year€455.09kno data
Maija Hollmen
Chief Scientific Officer2yrsno datano data
Vesa Karvonen
General Counselno datano datano data
Jennifer Smith-Parker
Head of Communicationsno datano datano data
Juhana Heinonen
Chief Commercial Officer6.9yrsno datano data
Petri Bono
Chief Medical Officerless than a yearno datano data

0.7yrs

Average Tenure

53yo

Average Age

Experienced Management: 4FR's management team is not considered experienced ( 0.7 years average tenure), which suggests a new team.

Board Members

NamePositionTenureCompensationOwnership
Juho Jalkanen
Founderless than a year€511.73kno data
Markku Jalkanen
Non- Executive Director18.2yrs€511.73k3.26%
€ 6.8m
Huaizheng Peng
Board Observer6.3yrs€36.20kno data
John Poulos
Independent Non-Executive Director7.6yrs€42.00k0.0096%
€ 19.9k
Tuomo Patsi
Independent Non-Executive Chairman1.8yrs€20.97k0.011%
€ 23.4k
Marie-Louise Fjallskog
Independent Non-Executive Director1.3yrsno datano data
Christophe Massard
Member of the Scientific Advisory Board5.3yrsno datano data
Amer Zeidan
Member of the Scientific Advisory Boardless than a yearno datano data
Toni Choueiri
Member of the Scientific Advisory Boardless than a yearno datano data
Christine Roth
Independent Non-Executive Director1.3yrsno datano data
Mika Kontro
Member of the Scientific Advisory Boardless than a yearno datano data
Tom Powles
Member of the Scientific Advisory Boardless than a yearno datano data

1.3yrs

Average Tenure

61yo

Average Age

Experienced Board: 4FR's board of directors are not considered experienced ( 1.3 years average tenure), which suggests a new board.

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/20 10:05
End of Day Share Price 2024/12/20 00:00
Earnings2024/06/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Faron Pharmaceuticals Oy is covered by 5 analysts. 4 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Patrick TrucchioH.C. Wainwright & Co.
Marianne PalmuInderes Oy
Antti SiltanenInderes Oy